We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+35.17%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$429M
AUM Growth
+$53.7M
Cap. Flow
-$13.3M
Cap. Flow %
-3.1%
Top 10 Hldgs %
66.36%
Holding
57
New
–
Increased
1
Reduced
6
Closed
1

Top Buys

Rank Stock Value
1
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$5.62M

Top Sells

Rank Stock Value
1
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$6.6M
2
IMCR icon
Immunocore
IMCR
+$3.81M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$2.65M
4
HLVX
HilleVax
HLVX
+$2.22M
5
RXRX icon
Recursion Pharmaceuticals
RXRX
+$2.18M

Sector Composition

Rank Sector Weight
1 Healthcare 98.01%
2 Financials 1.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KDNY
1
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$101M 23.66%
5,161,888
– –
NKTX icon
2
Nkarta
NKTX
$162M
$37.7M 8.8%
2,868,035
– –
SRRK icon
3
Scholar Rock
SRRK
$5.71B
$31.9M 7.43%
4,598,828
– –
LENZ
4
LENZ Therapeutics
LENZ
$172M
$26.8M 6.25%
1,208,473
– –
FMTX
5
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$21.3M 4.96%
1,065,413
-500,113
-32% -$6.6M
ACLX
6
DELISTED
Arcellx
ACLX
$20M 4.66%
1,063,835
– –
ISEE
7
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$14.5M 3.38%
808,041
-202,010
-20% -$2.65M
ACRS icon
8
Aclaris Therapeutics
ACRS
$730M
$11M 2.56%
696,171
– –
HLVX
9
DELISTED
HilleVax
HLVX
$10.4M 2.43%
610,062
-152,515
-20% -$2.22M
VRNA
10
DELISTED
Verona Pharma
VRNA
$9.6M 2.24%
938,890
-172,222
-15% -$1.45M
STRO icon
11
Sutro Biopharma
STRO
$379M
$9.3M 2.17%
167,558
– –
ICPT
12
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$8.94M 2.08%
640,688
– –
LYRA
13
DELISTED
LYRA THERAPEUTICS INC
LYRA
$8.9M 2.08%
35,545
– –
TIL icon
14
Instil Bio
TIL
$48.4M
$8.65M 2.02%
89,414
– –
RYTM icon
15
Rhythm Pharmaceuticals
RYTM
$7B
$8.46M 1.97%
345,293
– –
RAIN
16
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$7.62M 1.78%
1,560,652
– –
CNTA
17
DELISTED
Centessa Pharmaceuticals
CNTA
$6.81M 1.59%
1,693,736
– –
ZYME icon
18
Zymeworks
ZYME
$1.68B
$5.97M 1.39%
970,987
– –
PEPG icon
19
PepGen
PEPG
$133M
$5.91M 1.38%
651,050
– –
SYRS
20
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$5.68M 1.32%
881,450
+691,488
+364% +$5.62M
DICE
21
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$5.14M 1.2%
253,466
– –
JYAC
22
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$5.05M 1.18%
507,041
– –
JANX icon
23
Janux Therapeutics
JANX
$935M
$4.88M 1.14%
360,414
– –
DAWN
24
DELISTED
Day One Biopharmaceuticals
DAWN
$3.93M 0.92%
196,425
– –
IMCR icon
25
Immunocore
IMCR
$1.78B
$3.8M 0.89%
80,963
-80,000
-50% -$3.81M
1
2 3

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
GSIS
Global Strategic Investment Solutions Scottsdale, Arizona $1.03B AUM 16.75% 1-Year Est. Return
RIM
RW Investment Management Eagle, Idaho $1.03B AUM
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return

Samsara BioCapital's Q3 2022 Portfolio in Review

As of Q3 2022, Samsara BioCapital held 57 positions worth $429M, up 14% from $375M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Samsara BioCapital withdrew a net $13.3M in Q3 2022, closing 1 position and reducing 6 holdings. Its most notable exit was Recursion Pharmaceuticals, an estimated $2.18M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials.

Against the trend, Samsara BioCapital added an estimated $5.62M to Syros Pharmaceuticals, Inc. Common Stock.

  • Samsara BioCapital added most to Syros Pharmaceuticals, Inc. Common Stock in Q3 2022, an estimated $5.62M increase.
  • Samsara BioCapital's biggest Q3 2022 reduction was Forma Therapeutics Holdings, Inc. Common Stock, cutting an estimated $6.6M.
  • Samsara BioCapital fully exited Recursion Pharmaceuticals in Q3 2022, selling an estimated $2.18M.
  • Samsara BioCapital's ten largest holdings make up 66% of its $429M portfolio in Q3 2022.
  • Samsara BioCapital opened 0 new positions and closed 1 in Q3 2022.
  • Samsara BioCapital's portfolio value rose 14% quarter-over-quarter to $429M.

Based on Samsara BioCapital's 13F filing for Q3 2022, filed 14 Nov 2022.